Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mydecine Innovations Group Inc (OP: MYCOF )

0.1677 -0.0089 (-5.04%)
Streaming Delayed Price Updated: 12:29 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 898
Open 0.1691
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1766
Today's Range 0.1677 - 0.1691
52wk Range 0.1677 - 1.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Mydecine's Prospectus Supplement Closing Under Share Subscription And Management Update
Colorado-based next-generation psychedelics biotech Mydecine Innovations Group Inc. (OTC: MYCOF) announced that, in connection with its common share subscription agreement with a third-party investor... 
Via Benzinga
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Files Prospectus Supplement, Closes 1st Tranche of Subscription Agreement, Reappoints Board Member
Via Investor Brand Network

Performance

YTD
-60.54%
-60.54%
1 Month
-42.17%
-42.17%
3 Month
-59.84%
-59.84%
6 Month
-61.00%
-61.00%
1 Year
-76.04%
-76.04%

More News

Read More
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Via Benzinga
Mydecine's Q1 2023 Reports Shows Decline In Assets And R&D, Increase In Net Loss And Accumulated Deficit
Via Benzinga
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Results of Annual General Shareholders Meeting
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Mydecine Reports its 2023 Annual General Shareholders' Meeting Results
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Via Benzinga
New Set Of MDMA Analogs To Hit The Clinic: These Are The Latest Positive Findings
Via Benzinga
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Positive Preclinical Results on MYCO-006 Series
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property Product Safety
Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues
From Mydecine Innovations Group Inc.
Via GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Closes on Share Subscription Agreement
Via Investor Brand Network
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Filing of Prospectus Supplement, First Tranche Closing
Via Investor Brand Network
Mydecine: 2022 Financials & Business Update By Next-Gen Psychedelics Producer, Smoke Cessation Trial And More
Via Benzinga
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Issues Corporate Update
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Mydecine Innovations Group Provides Corporate Update
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Mydecine Reports Financial Results for the Year Ended December 2022
From Mydecine Innovations Group Inc.
Via GlobeNewswire
BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reports on Debt Settlement Agreements
Via Investor Brand Network
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
Via Benzinga
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Via Benzinga
Psychedelic Company Sale: Mydecine Gets Over $2.5M For Wholly-Owned Tech Subsidiary Business
Via Benzinga
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Closes Sale of Mindleap Health Inc.
Via Investor Brand Network
Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.
From Mydecine Innovations Group Inc.
Via GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Filing of Prospectus Supplement, Closing Under Share Subscription Agreement
Via Investor Brand Network
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.